KYMR - Kymera Therapeutics Inc Options
This article provides a detailed financial overview of Kymera Therapeutics Inc (KYMR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional ownership, and price performance over different periods. The data covers information up to July 02, 2026.
KYMR - Kymera Therapeutics Inc Volatility & Greeks
This article provides a detailed financial snapshot of Kymera Therapeutics Inc (KYMR), listing key metrics such as market capitalization, sales, earnings per share, and various financial ratios. It also includes information on volatility, share performance over different periods, insider and institutional ownership, and analyst recommendations. The data is current as of July 2, 2026, offering insights into the company's financial health and stock performance.
Kymera Therapeutics (KYMR) Stock Looks Fully Priced After A 405% Run
Kymera Therapeutics (KYMR) stock has seen a 405% return over three years but appears expensive based on Simply Wall St’s valuation checks, scoring 1 out of 6. The article questions whether the recent surge and high valuation leave enough room for investors, given the remaining risks in its development pipeline. The P/B ratio of 6.1x is higher than the biotech industry average, suggesting an aggressive pricing relative to typical biotech companies.
Kymera Therapeutics(KYMR.US) Officer Sells US$9.22 Million in Common Stock
A Kymera Therapeutics (KYMR.US) officer recently sold common stock valued at $9.22 million. This significant insider transaction could be noted by investors monitoring company leadership's actions.
Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics Inc (KYMR)
Noah Goodman, Chief Business Officer at Kymera Therapeutics Inc, sold 3,389 shares of the company on July 1, 2026. This sale follows a pattern of 45 insider sells against only 1 insider buy over the past year. The stock is currently trading at $114.29, which is significantly overvalued compared to its GF Value estimate of $22.94.
(SEC Amendment) Kymera Therapeutics(KYMR.US) Director Sells US$8.28 Million in Common Stock
A director at Kymera Therapeutics (KYMR.US) sold common stock valued at US$8.28 million. This information was disclosed in an SEC Amendment filing.
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
Kymera Therapeutics (KYMR) stock has risen 50.9% year-to-date due to strong investor optimism surrounding its lead drug candidate, KT-621, for atopic dermatitis and asthma. The company recently completed enrollment for its phase IIb BROADEN2 study ahead of schedule, with pivotal efficacy data expected by the end of 2026. Kymera also has several other pipeline programs and collaborations, including with Sanofi and Gilead Sciences, which are contributing to its long-term value proposition and providing milestone payments.
Form 144 Kymera Therapeutics For: 2 July By Investing.com
This article announces the filing of Form 144 for Kymera Therapeutics (KYMR) on July 2nd, without providing further details on the content of the filing. It is presented within a news aggregator format by Investing.com, surrounded by various market data and other news headlines. The piece itself is very brief, focusing solely on the announcement of the form filing.
Kymera Therapeutics(KYMR.US) Director Sells US$59.88 Million in Common Stock
A director at Kymera Therapeutics (KYMR.US) has recently sold common stock valued at US$59.88 million. This significant insider transaction indicates a major change in the director's holdings in the company. Further details regarding the transaction would be available in the official filings.
Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed?
Kymera Therapeutics
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $136
Truist Financial has reiterated its Buy rating on Kymera Therapeutics (KYMR.US) and set a target price of $136. This indicates the analyst firm's continued confidence in the company's stock performance.
KYMR Maintained by B. Riley Securities -- Price Target Raised to $155
B. Riley Securities has maintained a 'Buy' rating for Kymera Therapeutics (KYMR) and increased its price target from $117.00 to $155.00, indicating a projected 32.48% increase. Despite this optimistic outlook, GuruFocus indicates KYMR is significantly overvalued, trading at $108.05 against a GF Value of $22.70, and shows insider sales worth $311.9 million over the past three months. The company's GF Score of 46/100 highlights strong financial strength and momentum but poor profitability, growth, and valuation.
Kymera Therapeutics, Inc.(NasdaqGM: KYMR) added to Russell 2500 Value Benchmark
Kymera Therapeutics, Inc. (NasdaqGM: KYMR), a clinical-stage biopharmaceutical company, has been added to the Russell 2500 Value Benchmark. The company focuses on developing small molecule therapeutics that selectively degrade disease-causing proteins for immunology, with its programs targeting STAT6, IRF5, and IRAK4. This inclusion follows other recent additions to various Russell indices, reflecting increased market recognition.
Form 13D/A Kymera Therapeutics For: 26 June By Investing.com
This article announces the filing of Form 13D/A for Kymera Therapeutics on June 26, 2026. The brief entry provides the date of the filing and mentions Kymera Therapeutics (KYMR) with a -7.16% change. It appears to be an automated notification or a placeholder for more detailed information.
Kymera Therapeutics affiliated funds sell $173.7m in common stock
Affiliated funds of Kymera Therapeutics, including Biotechnology Value Fund, sold 1,630,658 shares of common stock for approximately $173.7 million at $106.50 per share. Despite the sale, the reporting group retains a significant stake and pre-funded warrants in the company. This news follows a 136% surge in the stock over the past year, placing it among the most overvalued according to InvestingPro analysis, even as the company makes clinical progress and announces leadership changes.
BVF funds sell 1.63M Kymera Therapeutics (KYMR) shares at $106.50
BVF and related entities sold 1,630,658 shares of Kymera Therapeutics (KYMR) at $106.50 per share on June 26, 2026, as detailed in an amended SCHEDULE 13D/A filing. Despite this sale, the group still beneficially owns approximately 6.3% of Kymera's common stock, totaling 5,237,151 shares. The filing also notes their holding of 1,365,099 pre-funded warrants and details the assignment of economic benefit from director Gorjan Hrustanovic's stock options to BVF Partners.
KYMR (NASDAQ) Form 144: Jefferies LLC files to sell 1.63M shares
Jefferies LLC has filed a Form 144 to sell 1,630,658 shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) Common Stock. The shares, valued at approximately $189.9 million, were acquired in 2020 via automatic conversion during the issuer's IPO. A Form 144 indicates a proposed sale and does not confirm execution, with further details expected from subsequent trade reports.
Enterprise value to revenue forward of Kymera Therapeutics, Inc. – BOATS:KYMR
This article provides financial information for Kymera Therapeutics, Inc. (KYMR) with a focus on its enterprise value to revenue forward. It appears to be a financial data page from TradingView, displaying the stock ticker, company name, and a specific financial metric. The content itself seems to be a placeholder for data that would typically be presented on such a financial overview page.
[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity
Bruce Booth, a director of Kymera Therapeutics, Inc. (KYMR), through associated venture funds Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a total of 398,765 shares of common stock in 30 open market transactions between June 23 and June 25, 2026. These sales, valued at approximately $43.99 million, were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025. The sales were made at weighted average prices ranging from approximately $99.95 to $119.0789 per share.
Truist Securities Adjusts Kymera Therapeutics PT to $136 From $116, Maintains Buy Rating
Truist Securities has raised its price target for Kymera Therapeutics (KYMR) shares to $136 from $116 while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the securities firm on the biopharmaceutical company. Kymera Therapeutics focuses on developing small molecule therapeutics that degrade disease-causing proteins for various conditions, particularly in immunology.
Kymera (KYMR) director receives 6,068 options at $99.87 strike price
Kymera Therapeutics director John Maraganore was granted 6,068 stock options with an exercise price of $99.87 per share, expiring on June 23, 2036. These options will vest in full on the earlier of June 24, 2027, or the date of Kymera’s next annual stockholder meeting. This transaction was reported as a grant rather than an open-market purchase, and the director directly owns all 6,068 options after the grant.
Director at Kymera Therapeutics (KYMR) receives stock options grant
Kymera Therapeutics director Jeffrey W. Albers has been granted stock options for 6,068 shares, which is a compensation-related award. These options have an exercise price of $99.87 per share and are set to expire on June 23, 2036. The shares will fully vest on the earlier of June 24, 2027, or the company's next annual stockholder meeting.
Kymera Therapeutics KYMR Stock Jumps On Pipeline Momentum
Kymera Therapeutics (KYMR) stock surged 18.4% due to significant pipeline advancements, including positive preclinical lupus data for KT-579, a $20M milestone payment from Sanofi for KT-485, and clear Phase 1 data for KT-621 enabling its progression to global Phase 2b trials. The company also saw Felix Baker appointed as chairman, indicating strong strategic oversight. Despite a mixed financial overview with substantial R&D expenses, the market is valuing its robust degrader pipeline, with a strong balance sheet providing stability for future developments.
Kymera Therapeutics KYMR Jumps As Degrader Pipeline Advances
Kymera Therapeutics (KYMR) shares jumped 16.61% following bullish analyst upgrades and pipeline optimism, driven by strong preclinical data for its lupus drug KT-579, a $20M milestone payment from Sanofi for KT-485, and clean Phase 1 data for KT-621. Despite significant losses, the company maintains a robust cash position and is backed by a major pharmaceutical partnership and new board leadership, signaling a catalyst-driven trading opportunity for active investors.
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Kymera Therapeutics has completed enrollment in its global BROADEN2 Phase 2b trial for KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, nearly six months ahead of schedule. This acceleration allows for topline data readout by year-end 2026, with Phase 3 trials expected to begin by mid-2027. KT-621, which has Fast Track designation, is also being tested for eosinophilic asthma.
Kymera Therapeutics (KYMR) Extends Rally On Sanofi Milestone And Lupus Data
Kymera Therapeutics (KYMR) stock has surged by 17.92% due to positive clinical data and a significant partnership milestone with Sanofi. The company received a $20 million payment upon Sanofi's first dosing of KT-485 and showcased promising preclinical data for its lupus drug KT-579, alongside strong Phase 1 results for KT-621 in Japanese trials. These developments highlight Kymera's robust immunology pipeline and its transition towards advanced clinical programs, attracting significant trader interest despite the company's current development-stage financial metrics.
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera Therapeutics (NASDAQ: KYMR) has announced the appointment of Felix J. Baker, Ph.D., as the new Chairman of its Board of Directors. Dr. Baker, who has served as Lead Independent Director since 2024, succeeds co-founder Bruce Booth, DPhil, who will remain an Independent Director. This leadership change comes as Kymera advances its pipeline of oral small molecule degrader medicines for immunological diseases.
Kymera Therapeutics (NASDAQ: KYMR) accelerates KT-621 Phase 2b AD data
Kymera Therapeutics announced that it has completed enrollment in its global BROADEN2 Phase 2b trial for KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, nearly six months ahead of schedule. This acceleration means the company now expects topline Phase 2b data by year-end 2026, instead of mid-2027, and plans to start Phase 3 trials in atopic dermatitis by mid-2027, subject to regulatory discussions. KT-621, which has FDA Fast Track designation for atopic dermatitis and eosinophilic asthma, is also being evaluated in a Phase 2b asthma trial with data anticipated in late 2027.
Kymera Therapeutics appoints Felix Baker as board chairman
Kymera Therapeutics has appointed Felix J. Baker as the new Chairman of its Board of Directors, succeeding co-founder Bruce Booth. Baker joined the board in 2024 and previously served as Lead Independent Director; he is also a Managing Member of Baker Brothers Investments. The announcement comes as Kymera Therapeutics, a clinical-stage biopharmaceutical company, nears a 52-week stock high, though some analysis suggests it may be overvalued.
Kymera Therapeutics appoints Felix Baker as board chairman By Investing.com
Kymera Therapeutics has announced the appointment of Felix J. Baker as the new Chairman of its Board of Directors, succeeding co-founder Bruce Booth. Baker, a managing member of Baker Brothers Investments and a board member since 2024, brings extensive experience to the clinical-stage biopharmaceutical company. This leadership change occurs as Kymera stock trades near its 52-week high, showing strong performance over the past year.
KYMR (NASDAQ: KYMR) Atlas Venture and Booth disclose multiple stock disposals
KYMR insiders and affiliated holders, including Atlas Venture funds and Bruce Booth, have filed Form 144 notices for proposed sales of common stock. These filings detail various transactions from April to June 2026, with specific share counts and gross proceeds indicating potential secondary supply. While Form 144 signals intent, the actual execution and market impact await confirmation through subsequent filings.
Kymera Therapeutics appoints Felix Baker as board chairman By Investing.com
Kymera Therapeutics has appointed Felix J. Baker as Chairman of its Board of Directors, succeeding co-founder Bruce Booth. Baker, a managing member of Baker Brothers Investments, will lead the board as the company, valued at $8.2 billion, trades near its 52-week high. The biopharmaceutical company continues to advance its clinical programs, recently receiving a milestone payment from Sanofi and presenting positive Phase 1 data for KT-621.
Kymera Therapeutics (NASDAQ: KYMR) wins support on directors, pay and 2026 auditor
Kymera Therapeutics (NASDAQ: KYMR) shareholders approved all management-backed proposals at their Annual Meeting on June 24, 2026. This included the re-election of four Class III directors, non-binding advisory approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026. All proposals passed with strong majority support from shareholders.
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera Therapeutics has announced the appointment of Felix J. Baker, Ph.D., as the new Chairman of its Board of Directors, succeeding co-founder Bruce Booth, DPhil, who will remain an Independent Director. Dr. Baker has been Kymera's Lead Independent Director since 2024 and brings extensive experience in scaling innovative companies in the biopharmaceutical sector. This leadership change comes as Kymera advances multiple mid- to late-stage programs and expands its oral degrader pipeline for immunological diseases.
Kymera taps Felix Baker as board chairman; Booth stays on
Kymera Therapeutics (NASDAQ: KYMR) has appointed Felix J. Baker, PhD, as the new Chairman of its Board of Directors, effective June 24, 2026. He succeeds co-founder Bruce Booth, DPhil, who will remain an Independent Director. Baker has been Kymera's Lead Independent Director since 2024 and leads Baker Brothers Investments, and his appointment is expected to provide experienced leadership as the company advances its oral degrader pipeline.
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
This announcement pertains to Kymera Therapeutics (KYMR) and concerns a notice of proposed sale of securities in accordance with Rule 144. The notice was filed with the SEC on June 24 at 06:14 and is indicated as a separate document. The content also includes extensive disclaimers regarding investment information.
KYMR (NASDAQ) affiliate sales reported — Atlas Venture and insiders disclose disposals
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has filed a Form 144 notice, indicating proposed sales of common stock by affiliated holders, including Atlas Venture funds and individuals. The filing details multiple past and proposed dispositions, with significant block sales occurring on June 22, 2026, and other transactions between April and June 2026. The notice, which is a routine disclosure, lists specific share counts and dollar amounts for these sales but does not state that the proceeds directly go to the issuer.
KYMR affiliates report large June share sales (NASDAQ: KYMR)
Affiliated entities of Kymera Therapeutics, Inc. (KYMR), including Atlas Venture funds and an individual, have reported significant sales of common stock in June 2026, as per Rule 144 filings. These transactions are specified with share counts and dollar amounts, such as Atlas Venture Fund X, L.P. selling 243,976 shares for over $24 million and Bruce Booth selling 11,741 shares for over $1 million. The article clarifies that these are affiliate dispositions and do not indicate proceeds received by the issuer.
Kymera Therapeutics CBO Noah Goodman sells $247,500 in stock
Kymera Therapeutics CBO Noah Goodman sold 2,500 shares of the company's common stock for $247,500 on June 22, 2026, at $99.00 per share, through a Rule 10b5-1 trading plan. This transaction occurred near the stock's 52-week high, and follows an acquisition of 2,500 shares via stock option exercise on the same day. The stock has seen a significant 117% gain over the past year, though InvestingPro analysis suggests it may be overvalued.
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics (KYMR) stock surged 10% following increasing investor confidence in its pipeline, particularly its lead candidate KT-621 for inflammatory diseases, with phase II data due in 2027. The company is projected to report a narrower quarterly loss and significant revenue growth, and positive revisions to earnings estimates suggest potential for further price appreciation. The stock currently holds a Zacks Rank #3 (Hold).
Why Kymera Therapeutics (KYMR) Is Up 5.7% After Positive Cross-Population KT-621 Phase 1 Data
Kymera Therapeutics saw its stock rise by 5.7% after reporting positive Phase 1 data for its oral STAT6 degrader, KT-621, in healthy Japanese adults. The results showed rapid, sustained STAT6 degradation and a favorable safety profile consistent with previous non-Japanese data, supporting the inclusion of Japanese patients in global Phase 2b trials for chronic Type 2 inflammatory diseases. This cross-population consistency and the recent US FDA Fast Track designation for KT-621 in eosinophilic asthma are key factors for Kymera's investment narrative, though high R&D spend remains a significant risk.
Kymera Therapeutics(KYMR.US) Director Sells US$48.59 Million in Common Stock
A director at Kymera Therapeutics (KYMR.US) recently sold common stock valued at approximately $48.59 million. This significant insider transaction indicates a major change in the director's holdings in the company.
[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity
Kymera Therapeutics, Inc. reported insider sales of 31,798 shares of common stock by Atlas Venture funds, associated with director Bruce Booth. These sales, occurring on June 22, 2026, were executed at weighted average prices between $103-$104 per share under a pre-established Rule 10b5-1 trading plan. Despite the sales, the funds retain substantial holdings, indicating the transactions were routine and pre-planned.
Atlas funds tied to Kymera (KYMR) sell 478,198 shares in June
Entities linked to Kymera Therapeutics director Bruce Booth, primarily Atlas Venture Fund X and Atlas Venture Opportunity Fund I, sold a net of 478,198 shares of Kymera common stock between June 17-22, 2026. The sales, conducted through open-market transactions, were generally in the low-to-mid $100 range and were largely pre-scheduled under Rule 10b5-1 trading plans adopted in December 2025. Additionally, Booth personally exercised options for 11,741 shares at $20.00 and immediately sold them at an average of $89.98, retaining 28,127 fully vested options.
Kymera Therapeutics director Bruce Booth sells $45.3m shares By Investing.com
Kymera Therapeutics director Bruce Booth sold approximately $45.3 million worth of company stock through direct and indirect transactions between June 17 and June 22, 2026. These sales, executed under Rule 10b5-1 trading plans, occurred while the stock traded near its 52-week high and was identified as overvalued by InvestingPro. Following the transactions, Booth holds no direct shares, though associated entities retain significant indirect holdings.
Form 4 Kymera Therapeutics Inc For: 22 June By Investing.com
This article provides details about a Form 4 filing for Kymera Therapeutics Inc, dated June 22. It mentions the stock symbol KYMR and includes general market data and related financial news. The article indicates a positive change in KYMR's stock price.
Kymera (NASDAQ: KYMR) CBO exercises options and sells 2,500 shares at $99
Kymera Therapeutics' Chief Business Officer, Noah Goodman, exercised stock options for 2,500 shares at $21.05 per share and subsequently sold all 2,500 shares in an open-market transaction at $99.00 per share. These transactions, performed under a pre-arranged Rule 10b5-1 trading plan, resulted in a net sale of 2,500 shares worth $247,500, though Goodman still directly holds over 50,000 shares of common stock. The insider selling activity involved a favorable spread between the exercise price and the sale price.
KYMR (NASDAQ) insiders sell 243,976 shares across April–June 2026
Kymera Therapeutics, Inc. (KYMR) filed a Form 144, reporting the resale of 243,976 shares of Common Stock by various Atlas Venture funds and affiliated individuals. These transactions occurred between April and June 2026 and are linked to a private placement from March 2020. The filing details individual sales, share counts, and cash proceeds for the selling holders, indicating routine resale notices under Section 144.
[144] Kymera Therapeutics, Inc. SEC Filing
Kymera Therapeutics, Inc. (KYMR) filed a Form 144 SEC Filing, disclosing officer/affiliate sales mainly by Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P., and Bruce Booth. The sales occurred between April 14, 2026, and June 18, 2026, involving common stock obtained via a private placement on March 11, 2020. The filing details individual transaction share counts and cash amounts, highlighting significant sales such as 100,928 shares on June 18, 2026, with proceeds of $9,185,730.49.
Kymera Therapeutics stock hits all-time high at 103.17 USD
Kymera Therapeutics stock reached an all-time high of $103.17, reflecting a 121.91% one-year increase. Despite being deemed overvalued by InvestingPro, analysts maintain a Strong Buy rating, driven by positive clinical developments and investor confidence. The company recently received a $20 million milestone payment from Sanofi and reported promising Phase 1 results for KT-621, alongside strong preclinical data for KT-579, leading Brookline Capital Markets to raise its price target to $97.
